Lymphoid Leukemia
18
3
5
9
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
11.1%
2 terminated out of 18 trials
81.8%
-4.7% vs benchmark
0%
0 trials in Phase 3/4
67%
6 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (18)
Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Halt Aging in Survivors of Blood Cancers
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
Integrated Actionable Aging Assessment for Cancer Patients Pilot
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation
Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery
Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia